GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Cencora Inc (NYSE:COR) » Definitions » Beneish M-Score
中文

Cencora (Cencora) Beneish M-Score : -2.48 (As of Apr. 25, 2024)


View and export this data going back to 1995. Start your Free Trial

What is Cencora Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.48 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Cencora's Beneish M-Score or its related term are showing as below:

COR' s Beneish M-Score Range Over the Past 10 Years
Min: -2.85   Med: -2.47   Max: -1.76
Current: -2.48

During the past 13 years, the highest Beneish M-Score of Cencora was -1.76. The lowest was -2.85. And the median was -2.47.


Cencora Beneish M-Score Historical Data

The historical data trend for Cencora's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cencora Beneish M-Score Chart

Cencora Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.54 -2.17 -2.26 -2.65 -2.49

Cencora Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.53 -2.47 -2.43 -2.49 -2.48

Competitive Comparison of Cencora's Beneish M-Score

For the Medical Distribution subindustry, Cencora's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cencora's Beneish M-Score Distribution in the Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Cencora's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Cencora's Beneish M-Score falls into.



Cencora Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Cencora for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.0277+0.528 * 1.0142+0.404 * 1.053+0.892 * 1.1231+0.115 * 0.7318
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.9706+4.679 * -0.030787-0.327 * 0.9955
=-2.48

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was $21,598 Mil.
Revenue was 72252.833 + 68922.331 + 66947.043 + 63457.205 = $271,579 Mil.
Gross Profit was 2468.812 + 2253.452 + 2264.646 + 2295.442 = $9,282 Mil.
Total Current Assets was $44,859 Mil.
Total Assets was $64,690 Mil.
Property, Plant and Equipment(Net PPE) was $2,117 Mil.
Depreciation, Depletion and Amortization(DDA) was $1,084 Mil.
Selling, General, & Admin. Expense(SGA) was $5,418 Mil.
Total Current Liabilities was $50,773 Mil.
Long-Term Debt & Capital Lease Obligation was $4,186 Mil.
Net Income was 601.5 + 350.565 + 479.581 + 435.402 = $1,867 Mil.
Non Operating Income was 24.5 + -76.033 + -19.541 + -156.65 = $-228 Mil.
Cash Flow from Operations was 885.157 + 1826.811 + 744.935 + 629.508 = $4,086 Mil.
Total Receivables was $18,713 Mil.
Revenue was 62846.832 + 61174.149 + 60064.601 + 57719.446 = $241,805 Mil.
Gross Profit was 2145.953 + 1985.559 + 2015.369 + 2235.08 = $8,382 Mil.
Total Current Assets was $40,708 Mil.
Total Assets was $57,907 Mil.
Property, Plant and Equipment(Net PPE) was $2,140 Mil.
Depreciation, Depletion and Amortization(DDA) was $705 Mil.
Selling, General, & Admin. Expense(SGA) was $4,970 Mil.
Total Current Liabilities was $44,761 Mil.
Long-Term Debt & Capital Lease Obligation was $4,656 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(21598.185 / 271579.412) / (18712.571 / 241805.028)
=0.079528 / 0.077387
=1.0277

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(8381.961 / 241805.028) / (9282.352 / 271579.412)
=0.034664 / 0.034179
=1.0142

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (44858.731 + 2117.283) / 64690.297) / (1 - (40708.125 + 2139.782) / 57906.893)
=0.273832 / 0.260055
=1.053

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=271579.412 / 241805.028
=1.1231

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(704.845 / (704.845 + 2139.782)) / (1083.881 / (1083.881 + 2117.283))
=0.247781 / 0.33859
=0.7318

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(5417.803 / 271579.412) / (4969.78 / 241805.028)
=0.019949 / 0.020553
=0.9706

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((4185.944 + 50773.472) / 64690.297) / ((4656.029 + 44760.623) / 57906.893)
=0.849577 / 0.853381
=0.9955

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(1867.048 - -227.724 - 4086.411) / 64690.297
=-0.030787

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Cencora has a M-score of -2.48 suggests that the company is unlikely to be a manipulator.


Cencora Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Cencora's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Cencora (Cencora) Business Description

Traded in Other Exchanges
Address
1 West First Avenue, Conshohocken, PA, USA, 19428-1800
Cencora is one of three domestic leading pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health constitute over 90% of the U.S. pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.
Executives
Leslie E Donato officer: EVP & Chief Strategy Officer 227 WASHINGTON STREET, CONSHOHOCKEN PA 19428
Elizabeth S Campbell officer: Executive Vice President 1 WEST FIRST AVENUE, CONSHOHOCKEN PA 19428
Steven H Collis officer: President & CEO 1300 MORRIS DRIVE, SUITE 100, CHESTERBROOK PA 19087
Lazarus Krikorian officer: Senior Vice President 1300 MORRIS DRIVE, CHESTERBROOK PA 19087
Silvana Battaglia officer: Executive Vice President 227 WASHINGTON STREET, CONSHOHOCKEN PA 19428
Walgreens Boots Alliance, Inc. 10 percent owner 108 WILMOT ROAD, DEERFIELD IL 60015
Gina Clark officer: Executive Vice President 1300 MORRIS DRIVE, CHESTERBROOK PA 19087
Werner Baumann director 1 WEST FIRST AVENUE, CONSHOHOCKEN PA 19428
Lauren M Tyler director C/O ALLEGHANY CORPORATION, 1411 BROADWAY, 34TH FLOOR, NEW YORK NY 10018
Robert P. Mauch officer: Executive Vice President 1300 MORRIS DRIVE, CHESTERBROOK PA 19087
Redonda Miller director 303 WYMAN STREET, SUITE 300, WALTHAM MA 02451
Lorence H. Kim director C/O SERES HEALTH, INC., 161 FIRST STREET, CAMBRIDGE MA 02472
Walgreens Boots Alliance Holdings Llc 10 percent owner 108 WILMOT ROAD, DEERFIELD IL 60015
Lon R Greenberg director 460 NORTH GULPH ROAD, KING OF PRUSSIA PA 19406
John G. Chou officer: Executive Vice President 1300 MORRIS DRIVE, CHESTERBROOK PA 19087